Replies to post #66085 on Anavex Life Sciences Corp (AVXL)

[orveko_inc]

It's in the company's best interest to try and protect their assets from as many angles as possible. There are other applications that have already been published, probably others that are filed but unpublished, and probably others being drafted.

This is from the original abandoned application (13/201,271), filed in 2010:

All molecules present strong chemical affinities (sub-nanomolar to micromolar) for s-1 receptors with antagonistic action (except AdAE and AdPhAE which are weak agonists) and with nanomolar to micromolar affinities for s-2 receptors and agonistic action. Therefore, all molecules above and their derivatives are pro-apoptotic and only at very low concentrations or doses are anti-apoptotic. All molecules above are toxic to the cancer cells : colorectal, prostate, ovarian renal, pancreas, lung, gliomas, glioblastomas leukemia, lymphomas, melanomas, sarcomas and hepatoma, with antiproliferative and cytotoxic concentrations usually lower than 10 microMolar (µM),for more than 50 of the above derivatives. Outstanding cytotoxicity, in vitro and the corresponding in vivo anticancer activity in mice xenografts, is for the first time disclosed for QNC and AST : 3.0-5.0 µM for all the above cancer cells and an outstanding in vivo activity of QNC on primary (drug resistant) melanoma, in which Dacarbazine is inactive, or MB : lower than 1.0 µM in vitro for primary (drug resistant) melanoma or leukaemia and lung and close to 2.0 µM in breast, colon and glioblastomas confirmed in vivo, specially in primary melanoma. All these molecules make excellent and prototypical anticancer drug candidates due to their aptitude to, simultaneously, antagonize the neurogenic and, more exceptional, the neuropathic and inflammatory pain as recently demonstrated by the appropriate experimental protocols: hot plate, formalin, von Frey fibers and, principally, the protocols based on previous administration of paclitaxel, oxaliplatine and streptozocin which concern more specifically the neuropathic pain originating from chronic administration of anticancer drugs, from diabetes or other neurotoxic stimulus. The pharmacological profile of the above molecules is totally prototypical and original giving the possibility of a therapeutic synergy with the clinically used anticancer drugs with simultaneous antagonism and protection against the most grave secondary effects i.e., neuropathic pain and disability induced by the clinically used anticancer drugs.

This paragraph made it to the resubmitted application (14/205637) and ultimately the final patent (9180106) with only a few edits for punctuation.